Source: http://www.google.com/patents/US6413533?dq=7,339,580
Timestamp: 2014-09-15 02:12:14
Document Index: 694105938

Matched Legal Cases: ['application No. 09', 'application No. 09', 'application No. 09', 'application No. 09', 'application No. 09', 'application No. 09', 'application No. 09']

Patent US6413533 - Administering antiestrogen - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign in<nobr>Advanced Patent Search</nobr>PatentsThis invention provides the chemoprevention of prostate cancer and, more particularly, to a method of preventing prostate carcinogenesis comprising the steps of administering to a human subject having a precancerous precursor of prostate adenocarcinoma, a pharmaceutical preparation comprising a chemopreventive...http://www.google.com/patents/US6413533?utm_source=gb-gplus-sharePatent US6413533 - Administering antiestrogenAdvanced Patent SearchPublication numberUS6413533 B1Publication typeGrantApplication numberUS 09/531,472Publication dateJul 2, 2002Filing dateMar 20, 2000Priority dateMay 7, 1998Fee statusPaidAlso published asCA2390295A1, CA2390295C, CN1331463C, CN1420765A, EP1229903A1, EP1229903A4, WO2001034117A1, WO2001034117A9Publication number09531472, 531472, US 6413533 B1, US 6413533B1, US-B1-6413533, US6413533 B1, US6413533B1InventorsMitchell S. Steiner, Sharan RaghowOriginal AssigneeThe University Of Tennessee Research CorporationExport CitationBiBTeX, EndNote, RefManPatent Citations (23), Non-Patent Citations (107), Referenced by (9), Classifications (46), Legal Events (4) External Links: USPTO, USPTO Assignment, EspacenetAdministering antiestrogenUS 6413533 B1Abstract This invention provides the chemoprevention of prostate cancer and, more particularly, to a method of preventing prostate carcinogenesis comprising the steps of administering to a human subject having a precancerous precursor of prostate adenocarcinoma, a pharmaceutical preparation comprising a chemopreventive agent to prevent, prevent recurrence of, suppress or inhibit prostate carcinogenesis. The present invention provides a safe and effective method for suppressing or inhibiting latent prostate cancer and is particularly useful for treating subjects having elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), or who have a family history of prostate cancer.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4329364Sep 23, 1976May 11, 1982Schering CorporationAntiandrogenic agents and methods for the treatment of androgen dependent disease statesUS4474813May 24, 1982Oct 2, 1984Schering CorporationProstatic carcinomaUS4696949Jan 29, 1986Sep 29, 1987Farmos Group Ltd.Antitumor agents, antiestrogensUS4990538Aug 23, 1989Feb 5, 1991Harris Adrian LAdministering for the treatment of cancerUS5491173 *Jan 24, 1994Feb 13, 1996Orion-Yhtyma OyEstrogenic, antiestrogenic agents, antitumor agentsUS5571534 *Dec 10, 1992Nov 5, 1996Orion-Yhtyma OyDrug formulations for parenteral useUS5595722Jun 7, 1995Jan 21, 1997Neorx CorporationTransforming growth factor-beta activatorsUS5595985Dec 15, 1993Jan 21, 1997Endorecherche Inc.Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasiaUS5599844Sep 15, 1995Feb 4, 1997Neorx CorporationAdministering agent to elevate level of transforming growth factor betaUS5605700 *Mar 25, 1993Feb 25, 1997Orion-Yhtyma OyTopical administration of toremifene and its metabolitesUS5629007Mar 21, 1995May 13, 1997Eli Lilly And CompanyUsing benzoquinolin-3-one derivativesUS5635197Mar 21, 1995Jun 3, 1997Eli Lilly And CompanyTreatment and prevention of prostatic cancer metastasisUS5650425 *Apr 4, 1994Jul 22, 1997Pharmos CorporationAnticarcinogenic, antagonist, antitumor agents and antiinflammatory agentsUS5788964Aug 2, 1994Aug 4, 1998Orion-Yhtyma OyMethod for sensitization of cancer cells for killer cell mediated lysisUS6080877 *Jun 3, 1997Jun 27, 2000Neuromedica, Inc.TaxanesUS6265448 *May 7, 1999Jul 24, 2001The University Of Tennessee Research Corporationadministering toremifeneEP0095875A2May 20, 1983Dec 7, 1983Farmos Group Ltd.Novel tri-phenyl alkane and alkene derivatives and their preparation and useEP0415623A2Aug 21, 1990Mar 6, 1991Orion-Yhtym� OyToremifene or demethyltoremifene as hydroxytoremifene for the reversal of multidrug restistance of cancer cells against cytotoxic drugsEP0616529A1Dec 10, 1992Sep 28, 1994Orion Yhtymae OyDrug formulations for parenteral use.WO1994012162A1Dec 1, 1993Jun 9, 1994Alanen Kurki Leena MariaSyndecan stimulation of cellular differentiationWO1995026720A1Mar 31, 1995Oct 12, 1995Anat BiegonPermanently ionic derivatives of steroid hormones and their antagonistsWO1998058634A2Jun 18, 1998Dec 30, 1998Af Ursin KaijaIntratumoral administration of triphenylethylenes for the treatment of cancerWO1999056739A1 *May 7, 1999Nov 11, 1999Univ Tennessee Res CorpA method for chemoprevention of prostate cancer* Cited by examinerNon-Patent CitationsReference1"Chemoprevention Of Prostate Cancer: Guidelines For Possible Intervention Strategies", Journal of Cellular Biochemistry, Supplement 16H:140-145 (1992).2"Editorial: A New Actor In The Estrogen Receptor Drama-Entre ER-beta", Endocrinology vol. 138, No. 3, (1997).3"New Research Approaches In The Prevention And Cure Of Prostate Cancer", American Association For Cancer Research.4"When Is Intervention Warranted?", Journal Of Cellular Biochemistry, Supplement 16H:138-139 (1992).5"Editorial: A New Actor In The Estrogen Receptor Drama-Entre ER-β", Endocrinology vol. 138, No. 3, (1997).6Albert David S. et al. "An Overview Of Clinical Cancer Chemoprevention Studies With Emphasis On Positive Phase III Studies" Overivew of Diet Cancer 6928-6975 (1995).7Anttila M et al. "Pharmacokinetics Of The Novel Antiestrogenic Agent Toremifene In Subjects With Altered Liver and Kidney Function" Clin Pharmacol Ther 1995 Jun.; 57(6):628-35.8Awoniyi Caleb A. et al. "Neonatal Exposure To Coumestrol, A Phystoestrogen, Does Not Alter Spermatogenic Potential In Rats", Endocrine, vol. 7, No. 3, 337-341, Dec. 1997.9Bergan RC et al. "A Phase II Study Of High-Dose Tamoxifen In Patients With Hormone-Refractory Prostate Cancer." Clin Cancer Res 1999 Sep.; 5(9): 2366-73.10Black et al. "Uterine Bioassay of Tamoxifen, Trioxifene and a New Estrogen Antogonist (LY117018) in Rats and Mice" in Life Sciences, 1980, vol. 26, pp. 1453-1458.11Boehm S et al. "Estrogen Suppression As A Pharmacotherapeutic Strategy In The Medical Treatment Of Benign Prostatic Hyperplasia: Evidence For Its Efficacy From Studies With Mepartricin" Wien Klin Wochenschr Dec. 11, 1998; 110(23):817-23.12Bonkhoff H et al. "Estrogen Receptor Expression In Prostate Cancer and Premalignant Prostatic Lesions", American Jounral of Paibology, vol. 155, No. 2 Aug. 1999.13 *Bostwick, "Prospective Origins of Prostate Carcinoma: Prostatic Intraepithelial Neoplasia and Atypical Adenomatous Hyperplasia," Cancer, Vo.78, No. 2, Jul. 15, 1996.*14Brandes LJ et al. "Salutary Clinical Response Of Prostate Cancer To Antiandrogen Withdrawal: Assessment Of Flutamide In An In Vitro Paragdigm Predictive Of Tumor Growth Enhancement", Clin Cancer Res 1997 Aug.; 3(8): 1357-61.15Brawley et al., "Chemoprevention of Prostate Cancer" in Urology, 1994, vol. 43, No. 5.16Buelke-Sam J. et al. "The Selective Estrogen Receptor Modulator, Raloxifene: An Overview Of NonClinical Pharmacology And Reproductive And Developmental Testing", Reprod Toxicol 1998 May-Jun.; 12(3):217-21.17Buelke-Sam Judy et al. "The Selective Estrogen Receptor Modulator, Raloxifene: An Overview Of NonClinical Pharmacology and Reproductive Development Testing", Reproductive Toxicology vol. 12, No. 3 pp. 217-221, 1998.18Celine Martel et al. "Binding Characteristics of Novel Nonsteroidal Antestrogens to the Rat Uterine Estrogen Receptors", Pergamon, J. Steroid Biochem. Molec. Bio., vol. 64, No. 3-4, pp. 199-205, 1998.19Chang William Y et al. "Estrogen Receptor-beta: Implications For The Prostate Gland" The Prostate 40:115-124 (1999).20Chang William Y et al. "Estrogen Receptor-β: Implications For The Prostate Gland" The Prostate 40:115-124 (1999).21Cheng E et al. "Endocrinology Of The Prostate", Prostate Diseases, chapter 5- pp. 57-71.22Christian Rohlff et al. "Prostate Cancer Cell Growth Inhibition by Tamoxifen Is Associated With Inhibition of Protein linase C and Induction of p. 21" The Prostate 37:51-59 (1998) (C)1998 Wiley-Liss, Inc.23Christian Rohlff et al. "Prostate Cancer Cell Growth Inhibition by Tamoxifen Is Associated With Inhibition of Protein linase C and Induction of p. 21" The Prostate 37:51-59 (1998) �1998 Wiley-Liss, Inc.24Colletta Anthony A. et al. "Alternative Mechanisms Of Action Of Anti-Oestrogens" Breast Cancer Research and Treatment 31: 5-9, 1994.25Dhar JD et al. "Estrogen, Androgen and Antiestrogen Responses In The Accessory Organs Of Male Rats During Different Phases Of Life", Endocr Res 1998 May; 24(2): 159-69.26Fleton SA "Potential New Antiestrogens For The Treatment Of Breast Cancer", Highlights in Oncology Practice vol. 15, No. 2, 1997 pp. 47-52.27Foekens JA et al. "Expression Of Prostate-Specific Antigen (PSA) Correlates With Poor Response To Tamoxifen Therapy In Recurrent Breast Cancer", Br J Cancer 1999 Feb.; 79(5-6): 888-94.28Gershanovich et al., "A Phase III Comparison of Two Toremifene Doses to Tamoxifen in Postmenopausal Women with Advanced Breast Cancer", Breast Cancer Research and Treatment 45, 1997, pp. 251-262.29Gingrich et al., "Androgen-independent Prostate Cancer Progression in the TRAMP Model", in Cancer Research 57, Nov. 1, 1997, pp. 4687-4691.30Gingrich et al., "Metastatic Prostrate Cancer in a Transgenic Mouse", in Cancer Research 56, Sep. 15, 1996, pp. 4096-4102.31Gingrich et al., "Pathalogic Progression of Autochthonous Prostate Cancer in the TRAMP Model", Prostate Cancer and Prostatic Diseases, 1999, 2, pp. 70-75.32Greenwald "Expanding Horizons in Breast and Prostate Cancer Prevention and Early Detection", in J. Cancer Education, 1993, vol. 8, No. 2, pp. 91-107.33Greenwald et al. "Breast Cancer Prevention and Early Detection", pp. 93-106.34Griffiths K. et al. "Further Insights Into Endocrine Disease-Diet and Prostate Disease" An IPHC Teaching Programme.35Griffiths K. et al. "Further Insights Into Endocrine Disease�Diet and Prostate Disease" An IPHC Teaching Programme.36Hayes "A Randomized Comparison Of Tamoxifen, Trioxifene And A New Estrogen Antogonist (LY117018) In Rats Aand Mice" In Life Sciences, 1980, vol. 26, pp. 1453-1458.37Hayes et al. "Randomized Comparison of Tamoxifen and Two Separate Doses of Toremifenein Postmenopausal Patients with Metastatic Breast Cancer", Journal of Clinical Oncology, vol. 13, No. 10, 1995, pp. 2556-2566.38Hempstock J. et al. "Growth Inhibition Of Prostate Cell Lines In Vitro By Phyto-Oestrogens", British Journal Of Urology (1998). 82. 560-563.39Hietanen T "Open Phase II Study of High-Dose Toremifene as First-Line Therapy for Advanced Breast Cancer" in Oncology-May 1997; 11(5 Suppl 4): 37-40.40Hietanen T "Open Phase II Study of High-Dose Toremifene as First-Line Therapy for Advanced Breast Cancer" in Oncology�May 1997; 11(5 Suppl 4): 37-40.41Hobisch Alfred "Metastatic Lesions From Prostate Cancer Do Not Express Oestrogen And Progesterone Receptors" J. Pathol. 182: 356-361, 1997.42Horton J et al. "Tamoxifen In Advanced Prostate Cancer: An ECOG Pilot Study", Prostate 1988; 12(2):173-7.43Horton John et al. "Tamoxifen In Advanced Prostate Cancer An ECOG Pilot Study", The Prostate 12: 173-177 (1988).44Jordan VC "Toremifene As An Anticancer Agent", Cancer Invest 1990; 8(2)271.45Kamat AM et al. "Chemoprevention Of Urological Cancer", The Journal Of Urology, vol. 161. 1748-1760. Jun. 1999, pp. 1748-1760.46Kangas L "Development And Biochemical Pharmacology Of Toremifene, An Antiestrogenic Antitumor Drug", Acta Obstet Gynecol Scand 1991; 70(4-5): 399.47Karlsson S. et al. "A Two-Year Dietary Carcinogenicity Study Of The Antiestrogen Toremifene In Sprague-Dawley Rats" Drug Chem Toxicol 1996 Nov.; 19(4): 245-66.48Kellof GJ et al., "Strategies For Chemoprevention Of Prostate Cancer", Prostate Cancer and Prostate Disease (1988) 5. 107.49Kelloff et al., "Introductory Remarks: Development of Chemopreventive Agents for Prostate Cancer" in Journal of Cellular Biochemistry, 1992, Supplement 16H: 1-8.50Kuiper George G. J. M. "Cloning Of A Novel Estrogen Receptor Expressed In Rat Prostate And Ovary", Proc. Natl. Acad. Sci. USA vol. 93, pp. 5925-5930, Jun. 1996 Biochemistry.51Kuiper George G. J. M. "Interaction Of Estrogenic Chemicals and Phytoestrogens With Estrogen Receptor beta", Endocrinology vol. 139, No. 10 (1998).52Kuiper George G. J. M. "Interaction Of Estrogenic Chemicals and Phytoestrogens With Estrogen Receptor β", Endocrinology vol. 139, No. 10 (1998).53Kuiper George G. J. M. et al. "Comparison Of The Ligand Binding Specificity And Transcript Tissue Distribution Of Estrogen Receptors alpha and beta", Endocrinology vol. 138, No. 3, 863-870 (1997).54Kuiper George G. J. M. et al. "Comparison Of The Ligand Binding Specificity And Transcript Tissue Distribution Of Estrogen Receptors α and β", Endocrinology vol. 138, No. 3, 863-870 (1997).55Landstrom M, et al. Inhibitory Effects Of Soy and Rye Diets On The Development Of Dunning R3327 Prostate Adenocarcinoma in Rats, The Prostate 36: 151-161 (1998).56Lippman SM et al. "Cancer Chemoprevention", J Clin Oncol 1994 Apr.; 12(4):851-73.57Lucia et al., "Chemopreventive Activity of Tamoxifen, N-(4-Hydroxyphenyl)retinamide, and the Vitamin D Analogue Ro24-553 1 for Androgen-promoted Carcinomas of the Rat Seminal Vesicle and Prostate" in Cancer Research, 1995, vol. 55, pp. 5621-5627.58 *Martin et al., Fundam. Appl. Toxicol. 30, No. 1, pt. 2, 233, 1996 (abstract included).*59Martin R. Schneider et al. "Nonsteroidal Antiestrogens and Partial Estrogens with Prostatic Tumor Inhibiting Activity", Cancer Research Clinical Oncology Springer-Verlag 1986, J Cancer Res Clin Oncol (1986) 112: 258-265, pp. 258-265.60Miyata E et al. "Effects Of Tamoxifen, An Antiestrogen, On Rat Prostate Carcinogenesis by 3,2'-Dimethyl-4-Aminobiphenyl And Testerone Do Not Support An Estrogen Role In Testerone Promotion", Prostate 1997 Apr. 1;31(1)9-13.61Miyata E et al. "Effects Of Tamoxifen, An Antiestrogen, On Rat Prostate Carcinogenesis by 3,2′-Dimethyl-4-Aminobiphenyl And Testerone Do Not Support An Estrogen Role In Testerone Promotion", Prostate 1997 Apr. 1;31(1)9-13.62 *Montandon et al., Archives of Toxicology, (1994) 68 (4), 272-275 (abstract included).*63Moon R.C. et al. "Chemoprevention of MNU-Induced Mammary Tumorigenesis by Hormone Response Modifiers: Toremifene, RU 16117, Tamoxifen, Aminoglutethimide and Progesterone", Anticancer Research 14: 889-894 (1994).64Moon RC et al. "Chemoprevention of MNU-Induced Mammary Tumorigenesis by Hormone Response Modifiers: Toremifene, RU 16117, Tamoxifen, Aminoglutethimide and Progesterone", Anticancer Res 1994 May-Jun.; 14(3A): 889-93.65Moore et al. "Regulation of Cytoplasmic Dihydrotestosterone Binding in Dog Prostate by 17beta-Estadiol", in J. Clin. Invest. (C) The American Society for Clinical Investigation, Inc., vol. 63 Mar. 1979, pp. 351-357.66Moore et al. "Regulation of Cytoplasmic Dihydrotestosterone Binding in Dog Prostate by 17β-Estadiol", in J. Clin. Invest. � The American Society for Clinical Investigation, Inc., vol. 63 Mar. 1979, pp. 351-357.67 *Neri et al., Expert Opin. Invest. Drugs (1996), 627-635 (abstract included).*68Neubauer et al., "Endocrine and Antiprostatic Effects of Raloxifene (LY156758) in the Male Rat", The Prostate 23, 1993, pp. 245-262.69Nevalainen M.T. et al. "Estrogen and Prolactin Regulation of Rat Dorsal and Lateral Prostate in Organ Culture", Endocrinology, vol. 129, No. 2 pp. 612-618.70Nevalainen MT et al. "Expression and Hormone Regulation Of Prolactin Receptors in Rat Dorsal and Lateral Prostate", Endocrinology 1996 Jul.; 137(7): 3078-88.71Nevalanine et al. "Hormone Regulaation of Human Prostate in Organ Culture" Cancer Ress, vol. 53, No. 21, 1993, pp. 5199-5207, XO002117653.72Perry "High Dose Toremifene for Estrogen and Progesterone Receptor Negative Metastatic Breast Cancer: a Phase II Trial of the Cancer and Leukemia Group B (CALGB)", in Breast Cancer Res Treat-1995; 26(1): 25-40.73Perry "High Dose Toremifene for Estrogen and Progesterone Receptor Negative Metastatic Breast Cancer: a Phase II Trial of the Cancer and Leukemia Group B (CALGB)", in Breast Cancer Res Treat�1995; 26(1): 25-40.74Pienta KJ et al. "A Phase II Evaluation Of Oral Tamoxifen And Intermittent Intravenous Vinblastine In Hormone-Refractory Adenocarcinoma Of The Prostate"., Am J Clin Oncol 1996 Oct.; 19(5):500-3.75Pienta KJ et al. "Inhibition Of Prostate Cancer Growth By Vinblastine And Tamoxifen", Prostate1995 May; 26(5): 270-4.76Pollard, "Prevention of Prostate-Related Cancer in Lobund-Wistar Rats", The Prostate 39, 1999, pp. 305-309.77Potter et al., "A Mechanistic Hypothesis for DNA Adduct Formation By Tamoxifen Following Hepatic Oxidative Metabolism" in Carcinogenesis, 1994, vol. 15, No. 3, pp. 439-442.78Powles TJ "Status Of Antiestrogen Breast Cancer Prevention Trials" Oncology (Huntingt) 1998 Mar.; 12(3 Suppl 5): 28-31.79Price K. R. et al. "Naturally Occurring Oestrogens in Food-A review", Food Additives and Contaminants, 1985, vol. 2, No. 2, 73-106.80Price K. R. et al. "Naturally Occurring Oestrogens in Food�A review", Food Additives and Contaminants, 1985, vol. 2, No. 2, 73-106.81Prins Gail S. "Developmental Estrogenization Of The Prostate Gland", Prostate:Basic and Clinical Aspects pp. 245-263 (1997).82Prins Gail S. et al, "Neonatal Estrogen Exposure Up-Regulates Estrogen Receptor Expression In The Developing And Adult Rat Prostate Lobes*", Endocrinology 138: 1801-1809, 1997).83Pyrh�nen et al., "Comparison of Toremifene and Tamoxifen in Postmenopausal Patients with Advanced Breast Cancer: a Randomized Double-blind, the "Nordic' Phase III Study", British Journal of Cancer, 1997, 76(2), pp. 270-277.84Pyrh�nen et al., "Comparison of Toremifene and Tamoxifen in Postmenopausal Patients with Advanced Breast Cancer: a Randomized Double-blind, the �Nordic� Phase III Study", British Journal of Cancer, 1997, 76(2), pp. 270-277.85Richard Gams, MD "Phase 111 Trials of Toremifene vs Tamoxifen" Oncology vol. 11, No. 5, Supplement 4, May 1997.86Ritva Valavaara, MD, PhD "Reliability of Estrogen Receptors in Predicting Response To Antiestrogens", Oncology, vol. 11 No. 5 Supplement No. 4 pp. 14-18.87Shenfeld et al. "Androgen Deprivation Therapy", Chapter 37, Section III/Prostate Cancer, pp. 467-477.88Shirai et al. "Effects of Testosterone, Dihydrotestosterone and Estrogen on 3,2'-Dimethyl-4-Aminobiphenyl-Induced Rat Prostate Carcinogenesis" in Int. J Cancer: 57, 224-228 (1994).89Shirai et al. "Effects of Testosterone, Dihydrotestosterone and Estrogen on 3,2′-Dimethyl-4-Aminobiphenyl-Induced Rat Prostate Carcinogenesis" in Int. J Cancer: 57, 224-228 (1994).90Shughrue Paul J. et al. "Comparative Distribution Of Estrogen Receptor-alpha (Er-alpha) And beta (Er-beta) mRNA In The Rat Pituitary, Gonad, And Reproductive Tract" Steroids 63: 498-504, 1998, Elsevier Science Inc.91Shughrue Paul J. et al. "Comparative Distribution Of Estrogen Receptor-α (Er-α) And β (Er-β) mRNA In The Rat Pituitary, Gonad, And Reproductive Tract" Steroids 63: 498-504, 1998, Elsevier Science Inc.92Simard et al., "Keoxifene Shows Pure Antiestrogenic Activity in Pituitary Gonadotrophs", Molecular and Cellular Endocrinology 39, 1985, pp. 141-144.93Strauss L "Genistein Exerts Estrogen-Like Effects In Male Mouse Reproductive Tract", Molecular and Cellular Endocrinology 144 (1998)83-93, Elsevier Science Ireland Ltd.94Strom Sara S. et al. "Phytoestrogen Intake and Prostate Cancer: A Case-Control Study Using A New Database", Nutrition and Cancer, 33(1), 20-25. (1999).95Szarka CE et al. "Chemoprevention Of Cancer", Curr Probl Cancer 1994 Jan.-Feb.; 18(1):6-79.96 *Toremifene citrate by Schering Corporation, 1999 PDR 2842-2843.*97Treinen KA et al. An Evaluation Of The Novel Selective Estrogen Receptor Modulator, Idoxifene, For Effects On Reproduction In Rats And Rabbits:, Toxicol Sci 1998 Feb.; 41(2):199-207.98U.S. application No. 09/306,958, Steiner, et al., filed May 7, 1999.99U.S. application No. 09/436,208, Steiner, et al., filed Nov. 8, 1999.100U.S. application No. 09/531,472, Steiner, et al., filed Mar. 20, 2000.101U.S. application No. 09/660,184, Steiner, et al., filed Sep. 12, 2000.102U.S. application No. 09/660,191, Steiner, et al., filed Sep. 12, 2000.103U.S. application No. 09/660,197, Steiner, et al., filed Sep. 12, 2000.104U.S. application No. 09/707,766, Steiner, et al., filed Nov. 8, 2000.105West Neal B et al. "Estrogen and Progestin Receptors And Aromatase Activity In Rhesus Monkey Prostate" Endocrinology, vol. 1. 123, (1998).106Xiaolin Zi et al. Silibinin Decreases Prostate-Specific Antigen With Cell Growth Inhibition Via G1 Arrest, Leading To Differentiation Of Prostate Carcinoma Cells: Implications For Prostate Cancer Intervention:, Proc. Nsil. Acad. Sci, USA vol. 96, pp. 7490-7495, Jun. 1999. Medical Sciences.107Yu H et al. "Induction Of Prostate Specific Antigen Production By Steroids And Taxoxifen In Breast Cancer Cell Lines", Breast Cancer Res Treat 1994; 32(3)291-300.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS6899888Nov 27, 2002May 31, 2005Otx, Inc.Suppressing bone disordes such as decalcification or fractures in humans having prostate gland cancers by administering antiestrogen selected from triphenylethylene or toremifene; hormone inhibitorsUS7070816Dec 5, 2003Jul 4, 2006New Chapter, Inc.Methods for treating prostatic intraepithelial neoplasia with herbal compositionsUS7332525Jan 9, 2004Feb 19, 2008Castle Erik PAntiandrogens and estrogen receptor moderator; synergistic mixture; side effect reductionUS7461048 *Oct 13, 2006Dec 2, 2008Aureon Laboratories, Inc.Systems and methods for treating, diagnosing and predicting the occurrence of a medical conditionUS7467119Mar 14, 2005Dec 16, 2008Aureon Laboratories, Inc.Systems and methods for treating, diagnosing and predicting the occurrence of a medical conditionUS7483554Nov 17, 2004Jan 27, 2009Aureon Laboratories, Inc.Pathological tissue mappingUS7524866Feb 17, 2004Apr 28, 2009Gtx, Inc.Prevention and treatment of androgen�deprivation induced osteoporosisUS7702598Feb 21, 2008Apr 20, 2010Aureon Laboratories, Inc.Methods and systems for predicting occurrence of an eventWO2009040824A2 *Sep 24, 2007Apr 2, 2009Venkata Krishna Raju AlluriAnti-adipogenic compositions containing piper betel and dolichos bifloras* Cited by examinerClassifications U.S. Classification424/422, 424/452, 514/965, 424/464, 424/489, 424/433, 424/434, 514/944, 514/938International ClassificationA61K9/10, A61P43/00, A61K9/107, A61K47/36, A61K47/40, A61K9/48, A61K9/14, A61P35/00, A61K47/26, A61K45/00, A61K9/20, A61K9/06, A61K9/127, A61K9/08, A61K47/38, A61P5/32, A61K31/138, A61K31/00, A61K31/4535, A61K31/565, A61K45/06, A61K31/015Cooperative ClassificationY10S514/965, Y10S514/938, Y10S514/944, A61K31/4535, A61K31/015, A61K45/06, A61K31/565, A61K31/00, A61K31/138European ClassificationA61K31/565, A61K31/00, A61K45/06, A61K31/015, A61K31/138, A61K31/4535Legal EventsDateCodeEventDescriptionFeb 7, 2014REMIMaintenance fee reminder mailedDec 2, 2009FPAYFee paymentYear of fee payment: 8Dec 23, 2005FPAYFee paymentYear of fee payment: 4Jun 15, 2000ASAssignmentOwner name: UNIVERSITY OF TENNESSEE RESEARCH CORPORATION, TENNFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STEINER, MITCHELL S.;RAGHOW, SHARAN;REEL/FRAME:010905/0647Effective date: 20000531Owner name: UNIVERSITY OF TENNESSEE RESEARCH CORPORATION SUITERotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google